All In Biotech

Drug Trial Radar · NCT07549412

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,020 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,020

Planned (sponsor's estimate)

Start

May 6, 2026

Primary completion

Oct 16, 2029

Study completion Oct 16, 2029

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluridine/tipiracil (FTD-TPI) plus bevacizumab.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Precemtabart tocentecanDrug

    Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle.

  • BevacizumabDrug

    Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

  • Trifluridine/Tipiracil (FTD-TPI)Drug

    FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm 1, 2 and 3: Overall SurvivalTime frame: Time from date of randomization to death, assessed approximately up to average of 19 months

Locations

116 sites in 19 countries. Site status is shown where the registry gives one.

  • UCSF Mount Zion Medical Ctr

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP- Aurora

    Lone Tree, Colorado · Recruiting

  • Florida Cancer Specialists-Broadway

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists - St. Petersburg Bayfront

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists East - FCS EAST - West Palm Beach

    West Palm Beach, Florida · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • Illinois CancerCare PC

    Peoria, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Profound Research LLC at Cancer and Leukemia Center

    Sterling Heights, Michigan · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Saint Louis Park, Minnesota · Recruiting

  • Missouri Cancer Associates - 150518964

    Columbia, Missouri · Recruiting

  • White Plains Hospital Medical and Wellness PRIME

    White Plains, New York · Recruiting

  • Prisma Health Cancer Institute, ITOR, CRU

    Greenville, South Carolina · Recruiting

  • Avera Cancer Institute - 300127370

    Sioux Falls, South Dakota · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology, P.A. - Abilene - 300210366

    Abilene, Texas · Recruiting

  • Texas Oncology-South Austin

    Austin, Texas · Recruiting

  • Texas Oncology DFW

    Bedford, Texas · Recruiting

  • Texas Oncology- San Antonio

    San Antonio, Texas · Recruiting

  • Texas Oncology, P.A. - Tyler

    Tyler, Texas · Recruiting

  • Virginia Oncology Associates

    Newport News, Virginia · Recruiting

  • Blue Ridge Cancer Care - 300202915

    Roanoke, Virginia · Recruiting

  • Investigaciones Clinicas Moleculares ICM

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Centro Oncologico de Excelencia

    San Juan, Argentina · Recruiting

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina · Recruiting

  • Instituto de Oncologia de Rosario

    Rosario, Santa Fe Province, Argentina · Recruiting

  • GenesisCare North Shore (Oncology)

    St Leonards, New South Wales, Australia · Recruiting

  • Icon Cancer Centre Chermside

    Chermside, Queensland, Australia · Recruiting

  • Mater Misericordiae Ltd - PARENT

    South Brisbane, Queensland, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie

    Salzburg, Austria · Recruiting

  • AKH - Medizinische Universität Wien - Klinik für Innere Medizin 1

    Vienna, Austria · Recruiting

  • Cliniques Universitaires Saint-Luc - STL

    Brussels, Belgium · Recruiting

  • Grand Hospital de Charleroi - PARENT

    Charleroi, Belgium · Recruiting

  • UZA - Account 3

    Edegem, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • BC Cancer - Vancouver - BC Cancer Agency

    Vancouver, British Columbia, Canada · Recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Recruiting

  • University Health Network - Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.